Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04705051 · ClinicalTrials.gov registry record · Phase 3
Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT04705051 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 24 participants.
The verdict
NCT04705051, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
Primary Objective: -To determine the effect of early versus delayed treatment with venglustat on the total kidney volume (TKV) in participants at risk of rapidly progressive autosomal dominant polycystic kidney disease (ADPKD). Secondary Objective: * To determine the effect of early versus delayed treatment with venglustat on the renal function (estimated glomerular filtration rate \[eGFR\] \[Chronic Kidney Disease Epidemiology Collaboration {CKD-EPI} equation\]). * To characterize the safety profile of venglustat. * To evaluate the effect of venglustat on the lens by ophthalmological examination. * To evaluate the effect of venglustat on mood using Beck Depression Inventory-II (BDI-II).
Interventions
- DRUG Venglustat GZ402671
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-02-09 |
| Est. Completion | 2021-07-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04705051
The ClinicalTrials.gov registry entry for NCT04705051 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Venglustat GZ402671 is the first listed.
NCT04705051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04705051 about?
NCT04705051 is a clinical study titled "Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat". Primary Objective: -To determine the effect of early versus delayed treatment with venglustat on the total kidney volume (TKV) in participants at risk of rapidly progressive autosomal dominant polycystic kidney disease (ADPKD). Secondary Objective: * To determine the effect of early versus delaye...
What is the current status of trial NCT04705051?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2021-02-09. Estimated completion is 2021-07-13.
What interventions are being tested in trial NCT04705051?
The interventions under investigation include: Venglustat GZ402671 (DRUG).
Who is sponsoring clinical trial NCT04705051?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.